Saving Seafood

AquaBounty and Intrexon Developing Gene Edited Tilapia; Receive GMO Exemption

December 21, 2018 — SEAFOOD NEWS — AquaBounty and Intrexon announced this week that their jointly developed gene edited line of tilapia is “exempt from GM regulation” according to Argentina’s National Advisory Commission on Agricultural Biotechnology (CONABIA).

Intrexon is a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet. GM salmon farmer AquaBounty is a majority-owned subsidiary of Intrexon.

According to a press release, the engineered tilapia was developed using gene editing techniques and do not contain any foreign DNA or a new combination of genetic material. Because of this, the tilapia is not considered a genetically modified product in Argentina.

“We are focused on developing animal biotechnology for aquaculture and livestock through our subsidiaries to support sustainable food production in the U.S. and abroad,” LTG Thomas Bostick, PhD, PE, Chief Operating Officer of Intrexon, said in a statement. “We are pleased with Argentina’s leadership in establishing a transparent and predictable process for the advancement of products developed with gene editing techniques and see this as a critical development for companies seeking to bring highly innovative solutions to the global market using powerful and highly precise genetic tools. Moreover, enhancing regulatory certainty for products derived from biotechnology is critical to the future of agricultural innovation.”

The engineered tilapia has an improved fillet yield of 70%, a growth rate improvement of 16%, and a feed conversion rate improvement of 14%. The tilapia has a shortened time to harvest, which not only reduces input costs, but increases production output and reduces risk of disease.

AquaBounty CEO Ronald Stotish added that the company is “committed to advancing novel technologies into the marketplace to improve sustainability in aquaculture.” Stotish said that it’s through their collaboration with Intrexon that the company has been able to make “significant progress.”

This story was originally published on SeafoodNews.com, a subscription site. It is reprinted with permission.

Murkowski: Fight against Frankenfish isn’t over

May 4, 2018 — AquaBounty may have won federal approval on April 26 for a genetically engineered salmon facility in Indiana, but they won’t be able to produce GE salmon there, says Sen. Lisa Murkowski, R-Alaska.

The Alaska Republican’s comments on May 1 came in the wake of Federal Drug Administration approval of an application for an AquaBounty salmon facility in Indiana last week. The company began developing genetically engineered salmon in 1996 and received an FDA approval in 2005 to sell it for human consumption.

Murkowski said the fight against “Frankenfish” is not over and she would continue to push for clear labeling of the product if it is to enter into the U.S. marketplace and for proper oversight.

Genetically engineered salmon currently are evaluated under the FDA’s New Animal Drug Application, a program intended to oversee antibiotics and medicines used on animals and livestock.

Read the full story at the Cordova Times

 

False Claims about ‘Frankenfish’

March 24, 2016 — Alaska Sen. Lisa Murkowski says she opposes federal approval of genetically engineered salmon “for the health of both consumers and fisheries.” But there is no scientific evidence that suggests GE salmon will pose a significant risk to either.

Murkowski claims GE salmon may “interbreed with the wild stocks, and thus perhaps destroy them.” But GE salmon have been rendered sterile — meaning they can’t interbreed with wild salmon stocks. Geographic and physical confinement measures also limit the likelihood that the GE fish will escape and survive.

As for human consumption, scientists engineered GE salmon to grow faster than non-GE farm-raised salmon by inserting genes from two other fish into the genome of an Atlantic salmon. After these changes, the GE salmon remained nutritionally and physiologically comparable to non-GE salmon, according to Food and Drug Administration’s scientific assessments, so the agency deemed GE salmon “safe to eat.”

FDA Approves GE Salmon

The FDA approved GE salmon – marketed by AquaBounty Technologies Inc. as “AquAdvantage Salmon” – on Nov. 19, 2015. AquaBounty first submitted its application to the FDA in 1995.

By inserting DNA from other fish, the company’s scientists engineered Atlantic salmon to reach market size faster than non-GE farm-raised Atlantic salmon. As per AquaBounty’s FDA application, the GE salmon will only be raised and farmed in inland facilities on Prince Edward Island in Canada and in Panama.

AquAdvantage Salmon was the first GE animal (as opposed to a plant) approved for human consumption in the United States.

However, it’s unclear when the GE fish will reach supermarkets. Back in November, when the FDA approved the product, Ronald Stotish, the chief executive of AquaBounty, told the New York Times that “the salmon would not be in stores immediately because it would take about two years for even these fast-growing salmon to reach market size.”

In January, the FDA also issued a ban on the import and sale of GE salmon until the agency “publishes final labeling guidelines for informing consumers of such content,” the FDA said. The ban was the result of language Murkowski introduced into the 2016 fiscal budget, or omnibus, bill. 

False claims about GE salmon have come from politicians on both sides of the party divide. While Murkowski is a Republican, Rep. Jared Huffman, a Democrat from California, has said, for example, that “by approving GE salmon, the FDA is allowing the release of a new hybrid animal that could pose a danger to our wild salmon populations, damage the ecosystems they live in, and undermine our domestic commercial fisheries.”

But Murkowski has arguably been one of the most vocal and active opponents. On her website, she notes the importance Alaska’s fisheries to the economy of her state. According to the Alaska Department of Fish and Game, the “seafood industry contributes 78,500 jobs to the Alaskan economy and an estimated $5.8 billion annually with Bristol Bay sockeye salmon … representing some of the largest salmon … fisheries in the world.” For this reason, Murkowski has “supported Alaska’s fisheries … through legislation and her position on the Senate Appropriations Committee,” as her website says.

The day the FDA approved GE salmon, Murkowski voiced her opposition on the Senate floor, claiming the FDA’s decision was “quite disturbing news to any of us who care about our wild species of salmon.” Specifically, she questioned the FDA’s ability to certify that GE salmon don’t “interbreed with the wild stocks, and thus perhaps destroy them.” In that speech, and later press releases, Murkowski called particular attention to GE salmon’s threat to Alaskan salmon stocks.

Murkowski also said that as someone “who believes that the real thing is the best thing for our families,” she found the FDA’s approval of GE salmon “very troubling.” In fact, she said, “I don’t even know that I want to call it a fish,” and instead referred to the GE salmon as a “frankenfish” and an “organism” generally. Likewise, in a Nov. 23 press release, Murkowski said: “Genetically modifying salmon is messing with nature’s perfect brain food. The real thing is not only the safe choice, but it’s the best thing.”

Most recently, Murkowski said in a March 3 press release: “I still adamantly oppose the FDA’s approval of GE salmon, for the health of both consumers and fisheries.” In this release, Murkowski announced the introduction of her Genetically Engineered Salmon Labeling Act, cosponsored with Alaska Sen. Dan Sullivan and Washington Sen. Maria Cantwell.

This legislation calls for the market name of GE salmon to “include the words ‘Genetically Engineered’ or ‘GE.’ ” It would also authorize “an independent scientific review” of the effects of GE salmon on wild salmon stocks and for human consumption.

Read the full article at FactCheck.org

FDA must develop plan to label genetically engineered salmon, Congress says

December 17, 2015 — The sprawling federal spending bill unveiled this week on Capitol Hill included a small passage with potentially big implications in the food world.

In two paragraphs on page 106, lawmakers instructed the Food and Drug Administration to forbid the sale of genetically engineered salmon until the agency puts in place labeling guidelines and “a program to disclose to consumers” whether a fish has been genetically altered. The language comes just a month after FDA made salmon the first genetically modified animal approved for human consumption and represents a victory for advocates who have long opposed such foods from reaching Americans’ dinner plates. At the very least, they say, consumers ought to know what they are buying.

The fish in the spotlight is the AquAdvantage salmon, produced by Massachusetts-based AquaBounty. The Atlantic salmon contains a growth hormone from a Chinook salmon and a gene from the ocean pout — a combination to help it grow large enough for consumption in 18 months instead of the typical three years.

Read the full story at The Washington Post

 

GMO fish and the strangeness of American salmon

December 2, 2015 — Sometime in the next few years, an entirely new fish will appear on American plates. After several decades of biotech research and a final upstream push past the U.S. Food and Drug Administration last month, the AquaBounty AquAdvantage salmon, a genetically engineered species of fish, will go into commercial production. While modified plants like corn and soy abound in the American diet, this will mark the first time in history that an engineered animal has been approved for human consumption. The new fish’s genetic code is comprised of components from three fish: base DNA from an Atlantic salmon; a growth gene from a Pacific Chinook salmon; and a promoter, a kind of “on” switch for genes, from a knobby-headed eel-shaped creature called an ocean pout.

The salmon’s pathway to the market will involve a similarly complex formulation. The first phase of AquAdvantage production will take place in Canada, on Prince Edward Island. There, the all-female eggs will be rendered sterile through a pressure treatment. They will then be flown to Panama, where they’ll be hatched, raised to harvestable size, slaughtered, and imported into the U.S. as the familiar orange-hued fillets that Americans have come to prefer above all other types of fish. Though AquaBounty hopes that the costs of this circuitous route to market could be offset by the savings incurred from the fish’s rapid growth (the company claims that AquAdvantage reaches maturity in about half the time as unmodified fish), the company is hoping to eventually gain permission to farm the fish here at home. “In the longer run,” AquaBounty’s co-founder, Elliot Entis, wrote me in an e-mail, “the real payoff will be when inland recirculating facilities are built in the U.S.”

Read the full story at The New Yorker

Salmon breakthrough was driven by chance

November 25, 2015 — It was the early 1980s, and a group of Canadian fish farmers was hoping to find a way for salmon to thrive in the region’s frigid waters. So scientists in Newfoundland began experimenting with how to inject them with antifreeze proteins from an eel­-like creature known as ocean pout.

Instead, they found a way to make the fish grow more quickly.

That work, more than 30 years ago, led to the controversial breakthroughs that allowed AquaBounty Technologies, a biotechnology company in Maynard, to produce a rapidly growing salmon, which the Food and Drug Administration last week declared the first genetically altered animal fit for consumption.

“We thought if we can enhance the growth rate, that’s good for the industry, which can get fish to market faster,” said Garth Fletcher, a researcher at Memorial University in Newfoundland, who did the initial experiments that led to the creation of salmon that can grow twice as fast as those in the wild. Fletcher’s technique of inserting growth hormone from Chinook salmon and a “promoter gene” from ocean pout is now considered antiquated technology. But scientists say its commercial application heralds a new era of genetic engineering.  

Federal regulators on Thursday approved a Massachusetts biotechnology company’s bid to modify salmon for human consumption.

“We thought if we can enhance the growth rate, that’s good for the industry, which can get fish to market faster,” said Garth Fletcher, a researcher at Memorial University in Newfoundland, who did the initial experiments that led to the creation of salmon that can grow twice as fast as those in the wild.

Fletcher’s technique of inserting growth hormone from Chinook salmon and a “promoter gene” from ocean pout is now considered antiquated technology. But scientists say its commercial application heralds a new era of genetic engineering.

New techniques have allowed scientists to more precisely alter animal genomes by editing DNA to include or exclude beneficial or harmful traits. Researchers are now experimenting with modifying the genes of chickens so they don’t transfer avian flu, for example. They also want to develop pigs and cattle that are resistant to foot and mouth disease, and goats that produce a higher level of a microbial protein that may help treat diarrhea in people.

Read the full story at the Boston Globe

Blumenthal wants GMO salmon labeled

November 24, 2015 — HARTFORD — U.S. Sen. Richard Blumenthal joined consumer advocates in the Capitol on Monday to criticize last week’s approval of genetically modified salmon and to advocate for mandatory labeling changes.

“The genetically engineered salmon is bigger, it can be grown faster,” Blumenthal said, stressing the Food and Drug Administration will require no special labeling for the engineered fish at grocery stores and fish markets, even though it will contain the genetic material of a bottom-feeder fish called the ocean pout to speed its growth.

“I believe strongly that the consumers have a right to know,” Blumenthal, D-Conn., said during a morning news conference.

The FDA recently said its scientists “rigorously evaluated extensive data” from fish grower AquaBounty Technologies, along with peer-reviewed data.

“The data demonstrated that the inserted genes remained stable over several generations of fish, that food from the GE salmon is safe to eat by humans and animals, that the genetic engineering is safe for the fish, and the salmon meets the sponsor’s claim about faster growth,” the agency said.

Read the full story at Connecticut Post

FDA OK’s genetically modified salmon

November 20, 2015 — For the first time, Americans will be able to dine on a genetically altered animal, after federal regulators on Thursday approved a Massachusetts biotechnology company’s bid to modify salmon for human consumption.

After years of testing the company’s modified fish, regulators said there are no “biologically relevant differences” between the so-called AquAdvantage salmon and other farm-raised Atlantic salmon. Still, for the time being the FDA has barred the fish from being cultivated in the United States and has issued strict regulations to prevent the modified salmon from breeding with those in the wild.

The decision was a big win for AquaBounty, which began seeking approval in the 1990s for its technique of inserting growth hormone genes from Chinook salmon and an eel-like creature called ocean pout into the DNA of Atlantic salmon. The faster the fish grow, the more the company can produce and sell, potentially reducing overfishing of the oceans and developing a new source of food for a growing global population.

Company officials said the federal approval would create a new industry in the United States, which they say imports 95 percent of its Atlantic salmon. But it was unclear how long it might take before the fish appear in supermarkets.

“AquAdvantage salmon is a game-changer that brings healthy and nutritious food to consumers in an environmentally responsible manner, without damaging the ocean and other marine habitats,” Ronald L. Stotish, the chief executive of AquaBounty, said in a statement.

Read the full story at the Boston Globe